Literature DB >> 2121367

MHC class II-associated invariant chain contains a sorting signal for endosomal compartments.

O Bakke1, B Dobberstein.   

Abstract

The invariant chain (Ii) is a transmembrane protein that associates with the MHC class II molecules in the endoplasmic reticulum. Expression of Ii in MHC class II-negative CV1 cells showed that it acquired complex-type oligosaccharide side chains and was retained in endosomal compartments. To search for a sorting signal, we made progressive deletions from the cytoplasmic N-terminus of Ii. Deleting 11 amino acid residues resulted in a protein that was still sorted and retained in endosomal vesicles, whereas deletion of 15 or more amino acid residues resulted in a protein that became resident in the plasma membrane. Amino acids 12-15 are thus essential for intracellular transport to endosomal compartments. As Ii is intracellularly associated with the MHC class II molecules, it is proposed that Ii determines the intracellular transport route of these molecules.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121367     DOI: 10.1016/0092-8674(90)90137-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  166 in total

1.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

2.  Interaction of human immunodeficiency virus type 2 Vpx and invariant chain.

Authors:  H A Pancio; N Vander Heyden; K Kosuri; P Cresswell; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation.

Authors:  U Reusch; W Muranyi; P Lucin; H G Burgert; H Hengel; U H Koszinowski
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

4.  Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.

Authors:  G Moldenhauer; C Henne; J Karhausen; P Möller
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

5.  Kinetics and intracellular pathways required for major histocompatibility complex II-peptide loading and surface expression of a fluorescent hapten-protein conjugate in murine macrophage.

Authors:  D J Weaver; E W Voss
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

6.  Down-regulation of cell surface receptors is modulated by polar residues within the transmembrane domain.

Authors:  L Zaliauskiene; S Kang; C G Brouillette; J Lebowitz; R B Arani; J F Collawn
Journal:  Mol Biol Cell       Date:  2000-08       Impact factor: 4.138

7.  Differing processing requirements of four recombinant antigens containing a single defined T-cell epitope for presentation by major histocompatibility complex class II.

Authors:  L Colledge; M Y Sun ; W Lin; C C Blackburn; P A Reay
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

8.  Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity.

Authors:  Didi Matza; Frida Lantner; Yoel Bogoch; Liat Flaishon; Rami Hershkoviz; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

9.  A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination.

Authors:  Liusong Yin; Lawrence J Stern
Journal:  J Immunol Methods       Date:  2014-02-25       Impact factor: 2.303

10.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

Authors:  S Baskar; S Ostrand-Rosenberg; N Nabavi; L M Nadler; G J Freeman; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.